Clinical
Follow pivotal data releases and trial developments that create new strategic pressure for biotech and pharma operators.
50 signals
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.
CLINICAL
LITFULO (ritlecitinib) demonstrated significant improvement in facial and total repigmentation in patients with nonsegmental vitiligo in two Phase 3 trials.
CLINICAL
Ultomiris did not achieve statistical significance for event-free survival in HSCT-TMA patients compared to placebo.
CLINICAL
Sonesitatug vedotin demonstrated a statistically significant improvement in overall survival for patients with CLDN18.2-positive advanced gastric/GEJ cancers.
COMPETITIVE
In Phase 3 trials TRIUMPH-2 and TRIUMPH-3, retatrutide demonstrated significant weight loss in adults with obesity and type 2 diabetes, and severe obesity with cardiovascular disease.
COMPETITIVE
Phase 3 ISLEND trials demonstrated high rates of virologic suppression at week 48 for the ISL/LEN regimen.
CLINICAL
KEYTRUDA (pembrolizumab) improved progression-free survival compared to platinum doublet chemotherapy in dMMR endometrial cancer patients.
CLINICAL
A Phase 3 study has been launched to assess the safety and efficacy of KarXT + KarX-EC for treating agitation in Alzheimer's patients.
COMPETITIVE
Phase 3 study aims to show neladalkib's superiority over alectinib in PFS for ALK-positive NSCLC.
CLINICAL
A Phase 3 clinical trial is underway to assess the combination of SHR-8068, Adebrelimab, and Bevacizumab with TACE in patients with incurable hepatocellular carcinoma.
CLINICAL
A Phase III trial is underway to compare the efficacy of TACE plus tislelizumab and lenvatinib against GEMCIS plus tislelizumab in patients with unresectable intrahepatic cholangiocarcinoma.
CLINICAL
The CARDIO-TTRansform Phase III trial for Wainua (eplontersen) did not meet its primary efficacy endpoint.
CLINICAL
A Phase III trial is underway to assess the efficacy and safety of Afimkibart in Crohn's disease patients.
CLINICAL
A Phase III study has been initiated to evaluate Toripalimab combined with Lenvatinib versus placebo in advanced HCC.
CLINICAL
A Phase III trial is underway to assess the efficacy and safety of Afimkibart in patients with moderately to severely active ulcerative colitis.
CLINICAL
The AASI-NSCLC trial is evaluating atezolizumab's effectiveness in preventing recurrence of stage I NSCLC after surgery.
CLINICAL
COMPETITIVE
Astria Therapeutics has initiated Phase 3 trial for navenibart in patients with hereditary angioedema.
CLINICAL
The Phase 3 trial for radiprodil in GRIN-NDD has commenced, focusing on efficacy and safety in two cohorts.
CLINICAL
AstraZeneca is conducting two pivotal Phase III studies to evaluate the efficacy and safety of elecoglipron in adults with obesity or overweight, with and without T2DM.
CLINICAL
The phase 3 study demonstrated that V116 met noninferiority and superiority criteria for immunogenicity compared to PPSV23 in children with chronic conditions.
CLINICAL
The INSIGHT trial is comparing durvalumab to standard observation in patients with early-stage non-small cell lung cancer post-surgery.
CLINICAL
A phase III trial is assessing the efficacy of cemiplimab in patients with surgically removed non-small cell lung cancer who have not received prior chemotherapy.
COMPETITIVE
Tulisokibart met its primary endpoint of clinical remission at 12 weeks in Phase 3 trial for ulcerative colitis.
COMPETITIVE
CLINICAL
The EVOLVE CLL/SLL study is comparing early versus delayed treatment with venetoclax and obinutuzumab in high-risk CLL/SLL patients.
Showing 1–25 of 50 records